PharmaEssentia’s Post

Always a fascinating area - how and when to use bone-modifying agents in metastatic hormone-sensitive prostate cancer. Some watch and wait (+/- serial bone density assessment), some use calcium/vit D only, others oral bisphosphonates and some IV bisphosphonates. This result will surely provoke even more debate and discussion in clinical practice - no OS benefit but a meaningful delay in time to SRE, which in itself is a valuable patient and system outcome. How will you apply these findings in your practice?

Considerations for Maintenance Therapy in the Community Oncology Setting: Key opinion leaders address the importance of coordination between academic hospital providers and community oncologists when transitioning from initiation of bispecific antibodies at a tertiary hospital to maintenance therapy in the community oncology setting. #finance #pharmacy #lifesciences

The success of precision oncology clinical trials depends on finding patients that meet strict criteria. So it’s crucial to identify and connect potential participants with aligned studies. Get our insights on clinical trial matching: https://bit.ly/3LpidEQ #Patientrecruitment #PatientsFirst #PatientErollment #ClinicalTrials #PrecisionOncology #ClinicalTrialMatching

Want an inside view of the changing face of oncology development? Get your free insights in partnership with IQVIA now: https://ow.ly/1OlI50Sq4yE. Download your free insight brief now to learn more about: • The current dose selection paradigm in oncology clinical trials • Dose optimization for better clinical trial outcomes • Patient-centricity and patient diversity • Complexity in combination therapies ... and more! #OncologyDevelopment #IQVIA #OncologyResearch #ClinicalResearch

Today, we announced a poster presentation at the American Society of Clinical Oncology (ASCO)) annual meeting highlighting interim results from the ongoing Phase 1 ELiPSE-1 study of CNTY-101 in relapsed or refractory (R/R) #lymphoma. The poster showcases CNTY-101’s continued encouraging preliminary efficacy and manageable safety profile for with no observed DLTs or GvHD. Learn more: https://bit.ly/3RaEI3k #ASCO2024

Check out this blog to learn the importance of human AME studies in understanding and assessing safety of new drugs as well as the applicability for oncology development programs. https://ow.ly/S83y50TuExe #oncologydrugs #cancerresearch #clinicalpharmacology #drugdevelopment

Our understanding of the molecular underpinnings of prostate cancer just in the past 5 years has made it imperative for Urologists and Urologic Oncologists to incorporate precision diagnostics throughout the continuum of care in patients with prostate cancer; from those considering active surveillance, to individuals with high grade localized cancer, to those with castrate resistant or metastatic disease. The implications are far reaching from prognosis, to therapy selection, to risk assessment and potentially genetic counseling. #PrecisionOncology #ProstateCancer

Want an inside view of the changing face of oncology development? Get your free insights in partnership with IQVIA now: https://ow.ly/RNGl50SpqRO. Download your free insight brief now to learn more about: • The current dose selection paradigm in oncology clinical trials • Dose optimization for better clinical trial outcomes • Patient-centricity and patient diversity • Complexity in combination therapies ... and more! #OncologyDevelopment #IQVIA #OncologyResearch #ClinicalResearch

Our Mission: We transform clinical outcomes by activating a network of oncology & hematology experts to promote confidence in treatment decisions and inspire a more informed path forward: one connection at a time. #CancerMission #CancerExperts #CancerNetwork #CancerSolutions

More than a quarter of the clinical trials reviewed by Bellberry in 2023 were in oncology. On International Clinical Trials Day we're highlighting the work of those involved in clinical trials with the release of our Clinical Trial Activity Report. If you would like a copy click here https://lnkd.in/gnXk9bwS #therapeutics #clinicaltrials #participantfocused #Australianresearch